Quanterix ((QTRX)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Quanterix’s latest earnings call painted a cautiously upbeat picture, blending solid reported growth and strong margins with clear signs of strain in its core research tools business. Management highlighted rising revenue, expanding non‑GAAP gross margins above 50% and substantial cost synergies, but also acknowledged sharp organic declines, pharma softness and ongoing execution risk as the company pushes toward cash‑flow breakeven.
Total Revenue Up, But Organic Declines Bite
Quanterix reported Q1 2026 revenue of $36.4 million, a 20% year‑over‑year increase helped by acquisitions and partner contributions. Under the surface, organic revenue slid 21%, underscoring weak demand in legacy Simoa and spatial product lines despite the headline growth.
Diagnostics Partners Deliver Strong Growth
Revenue from diagnostics partners jumped to $2.9 million from $1.6 million a year ago, an increase of about 81%. Management linked the gain to higher volumes of single‑biomarker tests through enablement partners, reinforcing diagnostics as a growing but still modest contributor.
Installed Base Underpins Competitive Position
The company now counts more than 2,300 instruments installed globally, giving it a sizeable footprint in proteomics and biomarker research. Executives cast Simoa as a leader in ultrasensitive digital immunoassays and its spatial platform as the highest‑plex proteomic system, assets they intend to leverage for future growth.
Cost Synergies From Akoya Acquisition Delivered
Quanterix said it has achieved the $85 million in annualized cost synergies promised from the Akoya acquisition, and will stop separately highlighting these savings after this quarter. Management framed the integration as substantially complete, positioning the combined business for improved operating efficiency.
Non-GAAP Gross Margins Stay Above 50%
Non‑GAAP gross profit reached $18.5 million in Q1, translating to a 50.9% non‑GAAP gross margin. The company reiterated a full‑year non‑GAAP gross margin outlook of 49% to 53%, suggesting it sees continued pricing and cost discipline even as volumes remain pressured.
Adjusted EBITDA Loss Narrows and Cash Burn Moderates
Adjusted EBITDA was a loss of $9.8 million, an improvement of $1.5 million versus the prior quarter as efficiencies began to flow through. Adjusted cash usage came in at $14.7 million, and management expects outflows to ease now that several annual payments have already been made.
Strong Cash Reserves and Debt-Free Balance Sheet
The company ended the quarter with $102.6 million in cash, cash equivalents, marketable securities and restricted cash, and carries no debt. Leaders signaled confidence that they can finish 2026 with roughly $100 million of cash, providing a buffer as they work toward profitability.
Stepped-Up Commercial and Diagnostics Investments
Quanterix is channeling resources into commercial execution, hiring a senior pharma partnerships leader, expanding lead generation and adding market development roles while integrating Thermo Fisher as a distribution partner. In diagnostics, it is recruiting leadership, upgrading the Simoa HD‑X platform for future regulatory filings, and investing in lab infrastructure and clinical utility studies.
Partnerships and Focused Product Roadmap
A key highlight was the partnership with Tempus AI to integrate the LucentAD Complete test into selected electronic health record systems, aiming to embed Quanterix assays into clinical workflows. At the same time, the company is streamlining its product roadmap, prioritizing HD‑X and folding lessons from the Simoa ONE early access program into future designs.
Core Organic Revenue Under Significant Pressure
Despite the reported growth, organic revenue fell 21% year‑over‑year, with both major platforms under pressure. Simoa organic revenue declined 21% while spatial revenue dropped 26%, reflecting softness in core research tool markets and slower customer spending.
Instrumentation Sales Weaken as Deals Slip
Instrumentation revenue was particularly soft at $4.0 million, split between $2.3 million for Simoa and $1.7 million for spatial systems. The company placed 16 Simoa and 11 spatial instruments, but noted several anticipated instrument deals were pushed into the second quarter.
Pharma and Academic Customers Pull Back
Pharma revenue tumbled 33% year‑over‑year, largely due to fewer large accelerator projects and reduced spatial placements, signaling caution in biopharma budgets. Pro forma academic revenue, which represents about 65% of the customer base, declined roughly 16%, underscoring broad‑based demand pressure.
Heavy One-Time Costs Weigh on Earnings
Operating expenses totaled $56.9 million, inflated by approximately $22 million in acquisition, integration, restructuring and purchase‑accounting costs. This included a $19 million one‑time write‑off of an intangible asset following the termination of an Akoya diagnostics development agreement, masking the underlying non‑GAAP cost base.
Persistent EBITDA Loss and Cash Usage Still a Risk
The company remains in the red, with a $9.8 million adjusted EBITDA loss and $19 million of cash used in the quarter, or $14.7 million on an adjusted basis. While trends are improving and management expects lower outflows, sustained losses keep liquidity and execution firmly in focus for investors.
Diagnostics Contribution Will Build Slowly
Management is taking a conservative stance on near‑term diagnostics revenue, not assuming any direct testing income in 2026. Partner‑driven diagnostic revenue is expected to hold around 2025 levels of roughly $10 million, implying that a more meaningful top‑line lift from diagnostics may come later.
End-Market Headwinds Continue to Drag
Executives acknowledged that end markets remain challenging, citing an academic funding slowdown and soft early‑year demand across customers. They stressed that near‑term growth is expected to come mainly from company‑specific initiatives rather than a broad recovery in research or pharma spending.
Guidance Holds as Management Targets H2 Inflection
Quanterix reaffirmed its 2026 outlook for revenue of $169 million to $174 million, GAAP gross margin of 41% to 45% and non‑GAAP gross margin of 49% to 53%. The company also expects Q2 revenue to be roughly in line with or slightly ahead of Q1, and continues to target cash‑flow breakeven in the second half of 2026 while ending the year with about $100 million in cash and no debt.
Quanterix’s earnings call showcased a business in transition, balancing strong reported growth, robust margins and delivered synergies against weakened organic demand and continued losses. For investors, the story hinges on whether commercial execution, diagnostics partnerships and a large installed base can offset end‑market softness and move the company to sustainable profitability over the next several quarters.